Literature DB >> 26439620

Neuroendocrine tumor G3: a pancreatic well-differentiated neuroendocrine tumor with a high proliferative rate.

Hiroki Tanaka1, Shimpei Matsusaki2, Youichirou Baba3, Yoshiaki Isono2, Hiroaki Kumazawa2, Tomohiro Sase2, Hiroshi Okano2, Tomonori Saito2, Katsumi Mukai2, Hiroshi Kaneko4.   

Abstract

A 68-year-old man was referred to our hospital because of left upper quadrant pain. Contrast enhanced computed tomography showed a low density mass with delayed contrast effects as well as para-aortic node swelling with homogenous contrast effects. Histological examination of specimens obtained by endoscopic ultrasound fine needle aspiration revealed a pancreatic neuroendocrine tumor (NET) G2, according to the World Health Organization 2010 classification, and lymph node metastasis. Distal pancreatectomy and lymph node dissection were performed. On histological examination, the tumor showed well-differentiated morphology with an organoid pattern. The Ki67 labeling index was 21.6 %, and the mitotic count was 25/10 high power fields. As mentioned above, we made a final diagnosis of the lesion as "NET G3," because the tumor presented with well-differentiated morphology. Chemotherapy with Everolimus was administered. Liver metastasis occurred 11 months after the first operation, and a partial hepatectomy was performed. Histological findings were similar to those of the first operation. Herein we present a case of pancreatic well-differentiated neuroendocrine tumor with a high proliferative rate referred to as "NET G3," and review the relevant literature.

Entities:  

Keywords:  EUS-FNA; NET G3; Neuroendocrine carcinoma; Neuroendocrine neoplasm; WHO 2010 classification

Mesh:

Substances:

Year:  2015        PMID: 26439620     DOI: 10.1007/s12328-015-0609-4

Source DB:  PubMed          Journal:  Clin J Gastroenterol        ISSN: 1865-7265


  25 in total

1.  Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors.

Authors:  Shinichi Yachida; Efsevia Vakiani; Catherine M White; Yi Zhong; Tyler Saunders; Richard Morgan; Roeland F de Wilde; Anirban Maitra; Jessica Hicks; Angelo M Demarzo; Chanjuan Shi; Rajni Sharma; Daniel Laheru; Barish H Edil; Christopher L Wolfgang; Richard D Schulick; Ralph H Hruban; Laura H Tang; David S Klimstra; Christine A Iacobuzio-Donahue
Journal:  Am J Surg Pathol       Date:  2012-02       Impact factor: 6.394

2.  The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms.

Authors:  Olca Basturk; Zhaohai Yang; Laura H Tang; Ralph H Hruban; Volkan Adsay; Chad M McCall; Alyssa M Krasinskas; Kee-Taek Jang; Wendy L Frankel; Serdar Balci; Carlie Sigel; David S Klimstra
Journal:  Am J Surg Pathol       Date:  2015-05       Impact factor: 6.394

3.  Ki67 labeling index in neuroendocrine tumors of the gastrointestinal and pancreatobiliary tract: to count or not to count is not the question, but rather how to count.

Authors:  Volkan Adsay
Journal:  Am J Surg Pathol       Date:  2012-12       Impact factor: 6.394

4.  Pancreatic neuroendocrine tumors: accurate grading with Ki-67 index on fine-needle aspiration specimens using the WHO 2010/ENETS criteria.

Authors:  Jessica M Farrell; Judy C Pang; Grace E Kim; Z Laura Tabatabai
Journal:  Cancer Cytopathol       Date:  2014-07-09       Impact factor: 5.284

5.  Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

Authors:  Eric Raymond; Laetitia Dahan; Jean-Luc Raoul; Yung-Jue Bang; Ivan Borbath; Catherine Lombard-Bohas; Juan Valle; Peter Metrakos; Denis Smith; Aaron Vinik; Jen-Shi Chen; Dieter Hörsch; Pascal Hammel; Bertram Wiedenmann; Eric Van Cutsem; Shem Patyna; Dongrui Ray Lu; Carolyn Blanckmeister; Richard Chao; Philippe Ruszniewski
Journal:  N Engl J Med       Date:  2011-02-10       Impact factor: 91.245

6.  Evaluation of Ki-67 index in EUS-FNA specimens for the assessment of malignancy risk in pancreatic neuroendocrine tumors.

Authors:  Toshiyuki Hasegawa; Kenji Yamao; Susumu Hijioka; Vikram Bhatia; Nobumasa Mizuno; Kazuo Hara; Hiroshi Imaoka; Yasumasa Niwa; Masahiro Tajika; Shinya Kondo; Tutomu Tanaka; Yasuhiro Shimizu; Taira Kinoshita; Takuhiro Kohsaki; Isao Nishimori; Shinji Iwasaki; Toshiji Saibara; Waki Hosoda; Yasushi Yatabe
Journal:  Endoscopy       Date:  2013-11-11       Impact factor: 10.093

7.  Survival and prognostic factor analysis in patients with metastatic pancreatic endocrine carcinomas.

Authors:  Jonathan Strosberg; Nancy Gardner; Larry Kvols
Journal:  Pancreas       Date:  2009-04       Impact factor: 3.327

8.  Are G3 ENETS neuroendocrine neoplasms heterogeneous?

Authors:  Fritz-Line Vélayoudom-Céphise; Pierre Duvillard; Lydia Foucan; Julien Hadoux; Cecile N Chougnet; Sophie Leboulleux; David Malka; Joël Guigay; Diane Goere; Thierry Debaere; Caroline Caramella; Martin Schlumberger; David Planchard; Dominique Elias; Michel Ducreux; Jean-Yves Scoazec; Eric Baudin
Journal:  Endocr Relat Cancer       Date:  2013-08-19       Impact factor: 5.678

9.  TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system.

Authors:  G Rindi; G Klöppel; H Alhman; M Caplin; A Couvelard; W W de Herder; B Erikssson; A Falchetti; M Falconi; P Komminoth; M Körner; J M Lopes; A-M McNicol; O Nilsson; A Perren; A Scarpa; J-Y Scoazec; B Wiedenmann
Journal:  Virchows Arch       Date:  2006-09-12       Impact factor: 4.064

10.  Does the WHO 2010 classification of pancreatic neuroendocrine neoplasms accurately characterize pancreatic neuroendocrine carcinomas?

Authors:  Susumu Hijioka; Waki Hosoda; Nobumasa Mizuno; Kazuo Hara; Hiroshi Imaoka; Vikram Bhatia; Mohamed A Mekky; Masahiro Tajika; Tsutomu Tanaka; Makoto Ishihara; Tatsuji Yogi; Hideharu Tsutumi; Toshihisa Fujiyoshi; Takamitsu Sato; Nobuhiro Hieda; Tsukasa Yoshida; Nozomi Okuno; Yasuhiro Shimizu; Yasushi Yatabe; Yasumasa Niwa; Kenji Yamao
Journal:  J Gastroenterol       Date:  2014-08-21       Impact factor: 7.527

View more
  4 in total

Review 1.  Management of Well-Differentiated High-Grade (G3) Neuroendocrine Tumors.

Authors:  Mohamad Bassam Sonbol; Thorvardur R Halfdanarson
Journal:  Curr Treat Options Oncol       Date:  2019-08-19

2.  Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System: The TOPIC-NEC Phase 3 Randomized Clinical Trial.

Authors:  Chigusa Morizane; Nozomu Machida; Yoshitaka Honma; Takuji Okusaka; Narikazu Boku; Ken Kato; Shogo Nomura; Nobuyoshi Hiraoka; Shigeki Sekine; Hirokazu Taniguchi; Naohiro Okano; Kensei Yamaguchi; Takuji Sato; Masafumi Ikeda; Nobumasa Mizuno; Masato Ozaka; Tomoko Kataoka; Makoto Ueno; Yuko Kitagawa; Masanori Terashima; Junji Furuse
Journal:  JAMA Oncol       Date:  2022-10-01       Impact factor: 33.006

3.  Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence.

Authors:  Lingaku Lee; Tetsuhide Ito; Robert T Jensen
Journal:  Expert Opin Pharmacother       Date:  2018-05-24       Impact factor: 3.889

4.  Recurrence of Pancreatic Neuroendocrine Tumors and Survival Predicted by Ki67.

Authors:  C G Genç; M Falconi; S Partelli; F Muffatti; S van Eeden; C Doglioni; H J Klümpen; C H J van Eijck; E J M Nieveen van Dijkum
Journal:  Ann Surg Oncol       Date:  2018-05-22       Impact factor: 5.344

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.